Drugs / gremubamab
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02255760 | Sep 2014 → Apr 2015 | pneumonia caused by pseudomonas aeruginosa infection | MedImmune LLC | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT02696902 | Mar 2016 → Dec 2019 | Pseudomonas aeruginosa infectious disease | MedImmune LLC | Completed | Missed primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2014-09-23 | AstraZeneca | Regulatory MedImmune receives fast track designation from FDA for development of MEDI3902 for prevention of nosocomial pneumonia astrazeneca.com ↗ |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2014-09-23 | AstraZeneca | MedImmune receives fast track designation from FDA for development of MEDI3902 for prevention of nosocomial pneumonia astrazeneca.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | gremubamab | “The bivalent, bispecific monoclonal antibody MEDI3902 (gremubamab) did not reduce PA nosocomial pneumonia incidence in PA-colonised mechanically ventilated subjects.” PMID 36380312 ↗ Nov 2022 |
| Known as | MEDI3902 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02255760 ↗ |
| Modality | Monoclonal antibody | “The bivalent, bispecific monoclonal antibody MEDI3902 (gremubamab)” PMID 36380312 ↗ Nov 2022 |
| Route | Intravenous | “single IV dose of MEDI3902” NCT02255760 ↗ |